Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities

Sabari Vallath, Robert E Hynds, Laura Succony, Sam M Janes, Adam Giangreco

Research output: Contribution to journalReview articlepeer-review

91 Citations (Scopus)


Chronic respiratory diseases, including pulmonary fibrosis, chronic obstructive pulmonary disease (COPD) and lung cancer, are the second leading cause of death among Europeans. Despite this, there have been only a few therapeutic advances in these conditions over the past 20 years. In this review we provide evidence that targeting the epidermal growth factor receptor (EGFR) signalling pathway may represent a novel therapeutic panacea for treating chronic lung disease. Using evidence from human patient samples, transgenic animal models, and cell and molecular biology studies we highlight the roles of this signalling pathway in lung development, homeostasis, repair, and disease ontogeny. We identify mechanisms underlying lung EGFR pathway regulation and suggest how targeting these mechanisms using new and existing therapies has the potential to improve future lung cancer, COPD and pulmonary fibrosis patient outcomes.

Original languageEnglish
Pages (from-to)513-22
Number of pages10
JournalEuropean Respiratory Journal
Issue number2
Publication statusPrint publication - Aug 2014
Externally publishedYes

Bibliographical note

©ERS 2014.


  • Animals
  • Chronic Disease
  • Disease Models, Animal
  • ErbB Receptors/antagonists & inhibitors
  • Humans
  • Inflammation
  • Lung/physiology
  • Lung Diseases/physiopathology
  • Lung Neoplasms/metabolism
  • Mice
  • Pulmonary Disease, Chronic Obstructive/physiopathology
  • Pulmonary Fibrosis/physiopathology
  • Signal Transduction
  • Treatment Outcome


Dive into the research topics of 'Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities'. Together they form a unique fingerprint.

Cite this